18 clinical trials found.
-
A Phase II Study of Ribociclib And Endocrine Treatment of Physician s Choice for Locoregional Recurrent Resected Hormone Receptor Positive HER2 Negative Breast Cancer (RaPhLRR Study).
You can participate in this study if you are diagnosed with Hormone Receptor (HR) positive, HER2 negative breast cancer (Stages I-II). The purpose of this ...Phase
TRIAL ROLE: Sub Investigator
-
A Phase 1b/2 Randomized Open-Label Study Investigating the Efficacy and Safety of LBL-007 Plus Tislelizumab in Combination With Bevacizumab Plus Capecitabine Versus Bevacizumab Plus Capecitabine as Maintenance Therapy in Patients With Unresectable or Metastatic Microsatellite Stable/Mismatch Repair Proficient Colorectal Cancer
The goal of the study is to find out if a new drug called LBL-007, given in combination with other drugs called tislelizumab, bevacizumab, and ...
Phase
TRIAL ROLE: Sub Investigator
-
OPTIMICE-PCR: DE-ESCALATION OF THERAPY IN EARLY-STAGE TNBC PATIENTS WHO ACHIEVE PCR AFTER NEOADJUVANT CHEMOTHERAPY WITH CHECKPOINT INHIBITOR THERAPY
This study is for patients with early-stage triple-negative breast cancer who received a treatment called pembrolizumab (a medicine used to treat melanoma). Some patients will ...Phase
TRIAL ROLE: Sub Investigator
-
A Phase 1 Clinical Trial of CA-4948 in Combination with Gemcitabine and NabPaclitaxel in Metastatic or Unresectable Pancreatic Ductal Carcinoma
This study is investigating the combination of CA-4948 and gemcitabine/nab-paclitaxel chemotherapy to find the highest dose that patients can take who have adenocarcinoma of ...Phase
TRIAL ROLE: Sub Investigator
-
A Phase 1b/2 Open-Label Umbrella Study to Evaluate Safety and Efficacy of Elacestrant in Various Combinations in Patients with Metastatic Breast Cancer (ELEVATE)
This is a study that is divided into two phases: Phase 1b and Phase 2. The Phase 1b part will test different combinations of drugs ...
Phase
TRIAL ROLE: Sub Investigator
-
I-SPY 2 TRIAL -Investigation of Serial Studies to Predict your Therapeutic Response with Imaging and Molecular Analysis 2
The I-SPY 2.2 study is a way to improve how we treat breast cancer. It uses a plan to test new treatments and find ...
Phase
TRIAL ROLE: Sub Investigator
-
A Randomized Open-Label Multicenter Phase 3 Trial of Domvanalimab Zimberelimab and Chemotherapy Versus Nivolumab and Chemotherapy in Participants with Previously-Untreated Locally Advanced Unresectable or Metastatic Gastric Gastroesophageal Junction and Esophageal Adenocarcinoma
This study is designed for patients who have Untreated Locally Advanced Unresectable or Metastatic Gastric, Gastroesophageal Junction, and Esophageal Adenocarcinoma
This is a phase 3 ...
Phase
TRIAL ROLE: Sub Investigator
-
A Randomized Open-Label Phase 3 Study of XL092 + Atezolizumab vs Regorafenib in Subjects with Metastatic Colorectal Cancer
You can participate in this study if you are diagnosed with cancer of the colon or rectum and your cancer progressed after or intolerant to ...Phase
TRIAL ROLE: Sub Investigator
-
A Phase 2 Study of XmAb 20717 in Patients With Selected Gynecological Malignancies and High-Risk Metastatic Castration-Resistant Prostate Cancer.
You can participate in this study if you are diagnosed with Cervical Cancer; Endometrial Cancer or Ovarian Cancer. The purpose of this study is to ...Phase
TRIAL ROLE: Sub Investigator
-
A Phase 1b Study of Nivolumab in Patients with Autoimmune Disorders and Advanced Malignancies (AIM-NIVO)
We want to know the safety and tolerability of the anti-programmed death 1 (PD-1) antibody nivolumab at different dose levels for patients with autoimmune disorders ...Phase
TRIAL ROLE: Sub Investigator
